Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
Date:5/17/2010

Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1 /2 clinical study combining MM-111 with Herceptin® (trastuzumab) in patients with advanced Her2 positive breast cancer.

Cambridge, Mass. (PRWEB) May 17, 2010 -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1 /2 clinical study combining MM-111 with Herceptin® (trastuzumab) in patients with advanced Her2 positive breast cancer.

MM-111 is a bi-specific antibody that targets tumor cells over-expressing ErbB2/HER2. MM-111 is designed to inhibit the signaling between ErbB2/HER2 and ErbB3/HER3 thus disabling the phosphatidylinositol 3-kinase (PI3K) pathway and preventing tumor proliferation.

“Our team is quite excited to test this combination in clinical trials given the preclinical data we have produced showing that MM-111 and Herceptin® have very complementary mechanisms of action,” said Clet Niyikiza, Ph.D., Executive Vice President of Development at Merrimack. “We believe that by combining the two candidates, we have the potential to treat a number of HER2 positive breast cancer patients who are not benefiting from current treatments.”

The Phase 1 /2 study will initially evaluate the human safety and pharmacokinetics of MM-111 in combination with Herceptin® and establish a safe regimen. The Phase 2 portion of the study will then investigate the regimen’s efficacy in the advanced Her2 positive breast cancer patient population. The trial is based on preclinical work showing that MM-111 and Herceptin® positively combine to inhibit the growth of ErbB2 over-expressing breast cancer cells. The Gabrail Cancer Center in Canton, Ohio, Huntsman Cancer Institute in Salt Lake City, Utah, and the Massachusetts General Hospital in Boston, Massachusetts, will participate in this study. The first patient in the study was enrolled at Huntsman Cancer Institute.

About MM-111
MM-111, a bi-specific antibody, binds to two different target proteins: ErbB2 and ErbB3. By binding to ErbB2 and ErbB3, MM-111 stops the signaling between these two cell receptors and disables their impact on the PI3K pathway. Deactivating the PI3K pathway has been shown to inhibit tumor growth. There are bi-specific antibodies in development that bind to different target proteins on different cells, but MM-111 is unique in that it binds to two different target proteins on the same cell. Pre-clinical data exhibiting MM-111’s impact on several ErbB2 positive cancer models, both as a monotherapy and in combination with Herceptin®, were presented at the 2009 and 2010 Annual Meeting of the American Association of Cancer Research. Merrimack has developed a broad intellectual property position around MM-111. This portfolio includes U.S. and international patent filings relating to compositions of matter and methods of use as well as licensed patents and pending patent applications, trade secrets and proprietary know-how.

About Merrimack
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Contact: Kathleen Petrozzelli, Corporate Communications, 617-441-1043, kpetrozzelli(at)merrimackpharma(dot)com; Betsy Raymond Stevenson, 860-984-1424, RaymondStevenson Healthcare Comms betsy(at)raymondstevenson(dot)com

# # #

Read the full story at http://www.prweb.com/releases/2010/05/prweb4007764.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
2. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
3. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
4. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
6. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
7. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
8. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
11. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017 "Surging application ... deployed by the government are expected to drive the ... The gesture recognition market is expected to be ... CAGR of 29.63% between 2017 and 2022. The touchless ... billion by 2022, growing at a CAGR of 17.44% ...
(Date:3/29/2017)... ... March 29, 2017 , ... ComplianceOnline, the leading governance, risk and compliance advisory ... Medical Device Summit 2017 venue and speaker lineup. The Summit will take place on ... , The Omni Parker House Hotel, which is located at 60 School Street, Boston, ...
(Date:3/29/2017)... DC (PRWEB) , ... March 29, 2017 , ... ... announced today that it is exhibiting in booth 513 at the Association of ... Washington, DC Downtown Hotel, March 29-31. , CANCERSCAPE unites key stakeholders from ...
(Date:3/29/2017)... GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company") announced today ... test for breast cancer, via its Virginia ... a blood-based biomarker test with a sophisticated algorithm to determine ... ... BreastSentry measures the fasting plasma levels of two biomarkers in ...
Breaking Biology Technology:
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
Breaking Biology News(10 mins):